Publish date: 8 August 2025
Our molecular pathology lab team are celebrating the arrival of a new machine that can screen a bigger range of genes, identifying more patients who are suitable for targeted lung cancer treatments and improving outcomes.
The machine, a Genexus Integrated NGS sequencer was funded through Rosemere Cancer Foundation.
Tom Christopherson, Senior Biomedical Scientist said “Previously, we have only been able to test for a few of these genes with the technology we have but now with the new machine we have available to us, we can test a greater number of genes. This increases the chances of finding gene change which the treating clinician will be able to act upon, giving the patient a wider range of treatment options as well as providing information that could be utilised in research. As this machine is using new technology, purchasing was always going to be costly.
However, the Rosemere Cancer Foundation were able to provide assistance with funding through charitable means to make this possible. This help from Rosemere was essential and with the support they have provided we will be able to bring these benefits to lung cancer patients across Lancashire and South Cumbria. We simply could not have done it without them. Thanks also to Blue Skies who worked with us and Rosemere to facilitate the purchasing process.”
